Wyeth Launches New Innovative Delivery System For Enbrel(R) (etanercept)

Enbrel (etanercept), Wyeth’s biological treatment for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis, is now available as a new easy-to-use pre-filled auto-injector device, known as the Enbrel MYCLIC pen.

The Enbrel MYCLIC pen is a single-use auto-injector, designed to deliver Enbrel as a 50mg subcutaneous injection. It has been developed to offer ease-of-use and enhance patient confidence with the injection process.

The Enbrel MYCLIC pen incorporates a number of features to help patients including a mechanism to prevent accidental or premature misfiring of the pen device, and a large window to display the progress of the injection. The pen also features an audible click to confirm that the injection has been completed. The design philosophy has been to minimise the opportunity for any patient confusion or mistakes.

Dr Vignesh Rajah, Wyeth’s Medical Director in the UK, says: “Extensive research has gone into the development of the Enbrel MYCLIC pen to ensure its ease-of-use and patient-friendliness. Our aim throughout has been to focus on features that enable the patient to feel comfortable with, and confident about, the injection process.”

“We believe patients with limited dexterity will, in particular, welcome the new Enbrel MYCLIC pen,” continued Dr Rajah. “In addition, patients who suffer from a fear of needles will appreciate the fact that the Enbrel MYCLIC pen has a needle safety shield to keep the needle hidden before, during, and after the injection.”

Dr Ali Jawad, Consultant Rheumatologist at the Royal London Hospital said “Looking at the day-to-day concerns of the patients we see, I am very pleased that an easy-to-use autoinjector system is being introduced for Enbrel patients. Enbrel has an established efficacy and safety profile in the treatment of rheumatoid arthritis and related conditions, and now, by improving the delivery system, Wyeth is taking a further important step forward in meeting the needs of patients and those who care for them.”

The Enbrel MYCLIC pen is licensed for use in all Enbrel adult indications and is available for both new and existing Enbrel patients. In addition to the new Enbrel MYCLIC pen (50mg dose), Enbrel continues to be available as a pre-filled syringe (25mg and 50mg doses) and as a powder for mixing with solvent solution (25mg dose).

Please note all patients should receive training from a healthcare professional familiar with the use of the device before using the Enbrel MYCLIC pen. Wyeth has been delivering a comprehensive healthcare professional training programme for the Enbrel MYCLIC pen prior to its launch for healthcare professionals.

Enbrel in rheumatoid arthritis (RA) 1

In RA Enbrel has been shown to significantly reduce the pain and swelling in patient’s joints, as well as the number of joints that are affected. Data also shows that the addition of Enbrel to an RA patient’s treatment can result in a nearly threefold reduction in the number of sick days taken in comparison to patients who are given methotrexate alone.2

Enbrel in psoriasis

Psoriasis patients receiving etanercept showed significant improvement in their disease severity measured by the Physician Global Assessment of Psoriasis (PGA) and Psoriasis Area and Severity Index (PASI) and achieved sustained and long-term relief of psoriasis symptoms. Data shows that mean improvement in PASI score was 68% at week 54 for continuous use of etanercept.3

Enbrel in ankylosing spondylitis (AS)

Currently biologics are an effective treatment for the spinal symptoms of AS and can have a significant impact on individuals. Enbrel has been shown to improve spinal mobility, back pain and inflammation in people with AS.4

References

1. Enbrel SmPC. medicines Last accessed September 1st 2009

2. Emery P et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. The Lancet, 2008; 372: 375-82.

3. Ortonne J P et al. Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to severe psoriasis over 54 weeks: the CRYSTEL study. Expert Rev. Dermatol. 3(6), 657-665 (2008
4. Martin Mola E et al. Long-term Efficacy and Safety, Including Patient-Reported Outcomes, With Etanercept for 5 Years in Ankylosing Spondylitis.

Source
Wyeth

View drug information on Enbrel.

UNICEF On The Ground In Myanmar Delivering Critical Supplies

Some 130 UNICEF technical and operations staff continued to travel to the areas affected by Cyclone Nargis today, identifying the greatest threats to children and women and delivering much-needed supplies.

“Time is of the essence,” said Ann M. Veneman, UNICEF Executive Director. “UNICEF had prepositioned emergency supplies, which staff in country are now distributing as quickly as possible, and more staff and supplies are on the way. In situations such as these, children are highly vulnerable to disease and hunger and they need immediate help to survive.”

In the wake of the disaster, lack of access to clean water and poor sanitation, inadequate shelter and poor nutrition pose particular risks to children. The risk of diarrhea increases and children are highly susceptible to this threat. Floods can also be a source of mosquito breeding and can lead to outbreaks of malaria and dengue fever, which are endemic in Myanmar. UNICEF water and sanitation experts are also concerned that the breakdown in the power supplies and sanitation systems may lead to a high risk of infections and water-borne diseases such as cholera and dysentery.

Emergency supplies that UNICEF had prepositioned and is now distributing include: family health kits with medicine for 155,000 people, water purifying solutions, oral rehydration salts, tarpaulins, UNICEF family kits (which include cooking and cleaning implements and jerry cans), bleaching drums.

The provision of gender-appropriate, protected latrines for displaced persons at camps is another priority. In addition, UNICEF is concerned about orphaned and separated children and is working with partners and the government to ensure their protection.

Women and children make up more than 60 per cent of Myanmar’s population, and are likely to be gravely affected. Experience shows that children are less able to physically defend themselves against such forces of nature and are more exposed to the dangers that follow in their path.

UNICEF has been present in Myanmar since 1950, with nine zonal offices and a head office in Yangon.

About UNICEF

UNICEF is on the ground in over 150 countries and territories to help children survive and thrive, from early childhood through adolescence. The world’s largest provider of vaccines for developing countries, UNICEF supports child health and nutrition, good water and sanitation, quality basic education for all boys and girls, and the protection of children from violence, exploitation, and AIDS. UNICEF is funded entirely by the voluntary contributions of individuals, businesses, foundations and governments.

unicef

Comment Issued To BBC Online Regarding The Effect Of The Menopause On Lung Function

Dr Victoria King, Research Development Manager at Asthma UK, says:

‘Research is beginning to show a link between menopause and asthma however it is too early to say exactly how menopause affects asthma symptoms and who is likely to be affected.

‘What is interesting about this study is that it supports previous findings which show that the effect the menopause may have on lung function is greater in lean women that have a lower body mass index.

‘We do know that some women find that their asthma gets worse when they are in a period of hormonal change so it is important to keep an eye on your asthma at these times and discuss any problems you have with your doctor or asthma nurse specialist.

‘If you have any concerns about your asthma and would like to talk in confidence to a trained asthma nurse you can call the Asthma UK Adviceline on 08457 01 02 03 open weekdays from 9am to 5pm.’

asthma

Barr Confirms Patent Challenge Of Razadyne(R) ER Capsules

Barr
Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that Janssen
Pharmaceutica N.V., Janssen, L.P., Ortho-McNeil Neurologics, Inc. and
Synaptech, Inc. (“Plaintiff”) filed suit against it and its subsidiary,
Barr Laboratories, Inc., relating to the patent protecting Razadyne(R) ER
(Galantamine Hydrobromide Extended-Release Capsules), 8 mg, 16 mg and 24
mg. The Company indicated it believes it is the first to file an
Abbreviated New Drug Application (ANDA) with the U.S. Food & Drug
Administration (FDA) for the product.

Barr filed an ANDA with the FDA for Janssen’s Razadyne ER (Galantamine
Hydrobromide Extended-Release Capsules), 8 mg, 16 mg and 24 mg in March
2006. Barr received notification from the FDA of the application’s
acceptance for filing in April 2006. Following receipt of notice from FDA,
Barr notified Janssen Pharmaceutica, N.V., the New Drug Application holder,
and Synaptech, the patent owner, of Barr’s challenge to the patent
protecting Razadyne(R) ER. Plaintiffs filed suit against Barr in the
District Court of New Jersey. This suit officially initiates the patent
challenge process under the Hatch-Waxman Act.

Razadyne ER is indicated for the treatment of mild to moderate dementia
of the Alzheimer’s type.

Razadyne ER had annual sales of approximately $54 million for the
twelve months ending May 2006, according to IMS sales data. Razadyne ER was launched in May 2005.

Barr Pharmaceuticals, Inc. is a holding company whose principal
subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc.,
develop, manufacture and market generic and proprietary pharmaceuticals.

Forward-Looking Statements

Except for the historical information contained herein, the statements
made in this press release constitute forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements can be
identified by their use of words such as “expects,” “plans,” “projects,”
“will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates”
and other words of similar meaning. Because such statements inherently
involve risks and uncertainties that cannot be predicted or quantified,
actual results may differ materially from those expressed or implied by
such forward-looking statements depending upon a number of factors
affecting the Company’s business. These factors include, among others: the
difficulty in predicting the timing and outcome of legal proceedings,
including patent-related matters such as patent challenge settlements and
patent infringement cases; the outcome of litigation arising from
challenging the validity or non- infringement of patents covering our
products; the difficulty of predicting the timing of FDA approvals; court
and FDA decisions on exclusivity periods; the ability of competitors to
extend exclusivity periods for their products; our ability to complete
product development activities in the timeframes and for the costs we
expect; market and customer acceptance and demand for our pharmaceutical
products; our dependence on revenues from significant customers;
reimbursement policies of third party payors; our dependence on revenues
from significant products; the use of estimates in the preparation of our
financial statements; the impact of competitive products and pricing on
products, including the launch of authorized generics; the ability to
launch new products in the timeframes we expect; the availability of raw
materials; the availability of any product we purchase and sell as a
distributor; the regulatory environment; our exposure to product liability
and other lawsuits and contingencies; the increasing cost of insurance and
the availability of product liability insurance coverage; our timely and
successful completion of strategic initiatives, including integrating
companies and products we acquire and implementing our new enterprise
resource planning system; fluctuations in operating results, including the
effects on such results from spending for research and development, sales
and marketing activities and patent challenge activities; the inherent
uncertainty associated with financial projections; changes in generally
accepted accounting principles; and other risks detailed from time-to-time
in our filings with the Securities and Exchange Commission, including in
our Annual Report on Form 10-K for the fiscal year ended June 30, 2005.
The forward-looking statements contained in this press release speak
only as of the date the statement was made. The Company undertakes no
obligation (nor does it intend) to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise, except to the extent required under applicable law.

Barr news releases and
corporate information are also available on Barr’s website
( barrlabs/). For complete indications, warnings and
contraindications, contact Barr’s Drug Information Department at 1-800-Barr
Lab. All trademarks referenced herein are the property of their respective
owners.]

Barr Pharmaceuticals, Inc.
barrlabs/

Non-invasive ventilation: new tool for the treatment of advanced COPD

Treatment of patients with advanced chronic obstructive pulmonary disease (COPD) frequently includes several non pharmacological approaches, such as pulmonary rehabilitation, lung volume reduction surgery and lung transplantation.
One additional method is the so-called non-invasive ventilation (NIV), based on a mechanical device which rhythmically blows air through a mask attached over the nose and mouth into the lungs of the patients.

For many years NIV has rendered conflicting results regarding its effectiveness, and adherence to the treatment has been rather poor. This was bad news for a treatment which is costly and time consuming.

In a recent study, Orlando Diaz (Catholic University, Santiago, Chile) and his Canadian and Chilean colleagues have challenged this notion.

The authors used a schedule which is different from current practices, to apply NIV. Instead of applying unsupervised NIV overnight at home, they used it during daytime, for only 3 hours a day, in ambulatory patients, under close supervision at the hospital.

Patients not only tolerated the procedure better than in previous studies, but also achieved clinically significant improvements in breathlessness during daily activities. These effects were clearly evident after only three weeks of treatment.
Another interesting finding was that the benefits obtained still persisted two weeks after suspension of NIV.

These new data suggest that NIV can be used intermittently for short periods, thus improving compliance and quality of life of patients with advanced disease that remain symptomatic despite full standard pharmacological therapy.

Title of the original article:
Physiological and clinical effects of diurnal noninvasive ventilation in hypercapnic COPD

The European Respiratory Journal is the peer-reviewed scientific publication of the European Respiratory Society (more than 7,500 specialists in lung diseases and respiratory medicine in Europe, the United States and Australia).

EUROPEAN RESPIRATORY JOURNAL (ERJ), Vol. 26, No 6
erj.ersjournals

ATS Issues Report On Emerging Issues In Hiv-Associated Pulmonary Disease

The American Thoracic Society has released a new report detailing recent global changes in the management of human immunodeficiency virus (HIV)-associated pulmonary disease. The report examines the evolving landscape of HIV and its associated diseases in areas where combination antiretroviral therapies (ART) are available, as well as offering insight into the trends occurring in areas of the world where ART use is limited.

The report appears in the March 1, 2011, issue of the Proceedings of the American Thoracic Society.

Since it first came to the public eye in the early 1980s, HIV infection has caused an estimated 25 million deaths worldwide. Patients whose immune systems are weakened by HIV infection historically have been prone to acute lung diseases and infections, most notably tuberculosis (TB) and pneumonia. However, with the introduction of combination antiretroviral therapy (ART) there has been a shift toward more chronic lung diseases among HIV-infected patients in countries where ART is widely available.

Because of the importance of HIV-associated pulmonary diseases and the rapidly evolving knowledge about their development and epidemiology, the American Thoracic Society convened a workshop to discuss current and emerging trends and issued a report based on those findings.

“In the early, pre-ART years of the HIV epidemic, pulmonary infections such as Pneumocystis pneumonia (PCP), TB and bacterial pneumonia were the most frequent pulmonary complications among HIV patients,” said Alison Morris, MD, associate professor of medicine and immunology, Division of Pulmonary, Allergy and Critical Care Medicine at the University of Pittsburgh School of Medicine. “Currently, infectious diseases are less common, although still prevalent, and diseases such as emphysema, pulmonary arterial hypertension (PAH) and lung cancer appear to be increasing. New syndromes associated with ART have also become important.

“Despite the importance of pulmonary diseases in HIV and the rapidly evolving understanding of their pathogenesis and epidemiology, few avenues exist for the discussion and dissemination of new clinical and basic insights,” she said. “This report summarizes the findings of the workshop members, and offers insight into the evolving landscape of HIV and its treatment.”

While shifts in disease conditions have occurred in areas of the world where ART is available and accessible, in areas where access to ART is limited HIV-infected patients still suffer from opportunistic pulmonary infections such as TB in low-income and middle-income countries where TB is endemic, and from PCP and bacterial pneumonia in the U.S. and Western Europe, she added. As a result, clinicians have been faced with treating a wider number of HIV-associated diseases.

“Pulmonary diseases are major causes of morbidity and death in people with HIV infection,” she said. “Millions of people with HIV and AIDS throughout the world are at risk of opportunistic pneumonias. However, the availability of combination antiretroviral therapy has turned HIV into a chronic disease, and noninfectious lung diseases are also emerging as important causes of illness. Understanding the differences among these populations can aid clinicians in identifying and treating HIV-associated pulmonary conditions.”

Recent research has also aided clinicians in developing a better understanding of HIV, which may in turn lead to new treatments, Dr. Morris added.

“Clinical understanding of the pulmonary immune response in HIV-infected people has greatly improved over the past several years, and now offers new possibilities for treatment and prevention of pulmonary disease,” she said.

Co-chairs of the workshop committee included Kristina Crothers, MD, of the University of Washington, James M. Beck, MD, of the University of Michigan, and Laurence Huang, MD, MAS, of the University of California, San Francisco.

“The epidemiology, manifestations and outcomes of pulmonary disease vary depending on availability of ART, and noninfectious conditions may become more common in the current era of the AIDS epidemic, particularly in those with access to ART,” Dr. Morris said. “We expect that pulmonary disease will continue to be an important co-morbidity in persons with HIV and continued research is needed to track these complications and explore new treatment modalities.”

Source: American Thoracic Society (ATS)

Combination Formoterol And Budesonide As Maintenance And Reliever Therapy Vs Inhaled Steroid Maintenance For Chronic Asthma In Adults And Children

Traditionally inhaled treatment for asthma has been considered as preventer and reliever therapy. The combination of formoterol and budesonide in a single inhaler introduces the possibility of using a single inhaler for both prevention and relief of symptoms (single inhaler therapy).

Extract from Implications for Practice

Single inhaler therapy can reduce the risk of asthma exacerbations needing oral corticosteroids or hospital admission in comparison with fixed dose maintenance inhaled corticosteroids. Guidelines and common best practice suggest the addition of regular long-acting beta2-agonist to inhaled corticosteroids for uncontrolled asthma, and single inhaler therapy has not been demonstrated to reduce exacerbations in comparison with current best practice, although results of five large trials are awaiting publication. Single inhaler therapy is not currently licensed for children under 18 years of age in the United Kingdom.

(CD007313) by Cates and Lasserson

The Cochrane Library contains high quality health care information, including Systematic Reviews from The Cochrane Collaboration. These Reviews bring together research on the effects of health care and are considered the gold standard for determining the relative effectiveness of different interventions. The Cochrane Collaboration is a UK registered international charity and the world’s leading producer of systematic Reviews. It has been demonstrated that Cochrane Systematic Reviews are of comparable or better quality and are updated more often than the Reviews published in print journals.

The Cochrane Library can be accessed at thecochranelibrary. Guest users may access abstracts for all Reviews in the database, and members of the media may request full access to the contents of the Library.

Source
The Cochrane Library

The Politics Of Clean Air

Cultural differences between countries run right to the heart of government, thereby influencing technological innovation. This is reported in a comparative study by David Calef and Robert Goble published recently in the journal Policy Sciences(1). The authors outline efforts taken throughout the 1990s by both the US and French governments to adopt legislation fostering technological innovation to improve urban air quality by promoting clean vehicles, specifically electric vehicles (EVs). The study highlights the differences in approach and policy-making style by both governments and how this might have affected the final outcome.

In the Californian example, mandates were instituted that required zero-emission vehicles (ZEVs) to make up a certain percentage of car production and sales, with fines imposed for not reaching targets. Both the oil and auto industries opposed this and lobbied heavily against it. There was intensive media coverage of the debate and environmentalists spoke out on both sides. All parties were locked in a confrontational relationship fueled by a longstanding mutual mistrust. Public participation was openly sought.

The French mandate, however, was characterized by heavy government involvement. Much of the interaction between government and businesses was conducted ‘behind closed doors’, free of public scrutiny. Unlike in the US, no group ever complained that EVs were a problem. A treaty was made between the state-owned electricity company, the auto industry and local administrative institutions to contribute to the development of the EV. No penalties were imposed for failing to meet targets. Subsidies were provided to encourage individuals to buy EVs.

The diversity in the policies adopted reflect both practical and cultural differences between the USA and France. American cities are characterized by urban sprawl (which makes EVs difficult to use), the gasoline tax is low and the environmental lobby is political and vocal. France’s cities, conversely, have a typically dense layout making EVs more practical. The nuclear power industry has little opposition and has excess capacity to provide electricity. Awareness of green issues in France is low and the high gasoline tax is a substantial source of revenue for the government.

In the end, the different ways used to achieve the same goal had no effect on the outcome. Both countries failed to reduce urban pollution in line with targets. However, the stricter legislation in the USA compelled the automotive industry to come up with an alternative solution which it did in the form of hybrid cars. This is typical, the authors observed, because in the US, technological solutions are preferred over behavioral change. In France, technological solutions are strongly related to national prestige as a form of cultural elitism. France failed to make this a ‘grand project’ and the lack of public awareness may have failed to drive it forward.

This comparison shows that individual cultures still have ‘standard operating procedures’ which reflect ‘deep-rooted national political and social cultures’ despite increasing globalization. It also suggests that governments should take into account the cultural dimension when promoting policy change.

1. Calef D and Goble R (2007). The allure of technology: How France and California promoted electric and hybrid vehicles to reduce urban air pollution. (Policy Sciences, Vol. 40, No. 1, DOI 10.1007/s11077-006-9022-7)

The full-text article can be viewed free of charge at springerlink/content/1573-0891.

Contact: Joan Robinson

Springer

Ferring Pharmaceuticals Unveils Six-Month Efficacy Data For EUFLEXXA(R) For The Treatment Of Osteoarthritis Knee Pain

Ferring Pharmaceuticals recently presented the results of a six-month safety and efficacy study demonstrating that EUFLEXXA(R) (1% sodium hyaluronate) was effective at decreasing the pain of knee osteoarthritis (OA) at 26 weeks. The study showed that EUFLEXXA (R) is superior to saline in decreasing pain at 26 weeks in patients with OA of the knee.(1) The study results were presented by Dr. Roy D. Altman in a poster at the Annual Meeting of the American Academy of Orthopedic Surgeons on February 23, 2009.

EUFLEXXA(R) is a three-injection treatment regimen indicated for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. The goal of hyaluronic acid (HA) therapy is to reduce pain and improve physical function by replenishing the HA in human synovial fluid (fluid in joints). In OA, this fluid becomes thinner, leading to a decrease in elasticity and viscosity.

About the Study

The multicenter, 26-week, randomized, double-blind trial compared EUFLEXXA(R) and intra-articular buffered saline (IA-SA) for level of pain following a 50-Foot Walk Test, measured by 100 mm visual analog scale (VAS). The 586 patients with chronic idiopathic knee OA were randomized to treatment with either product in a 1:1 ratio. Each patient received one weekly injection for 3 weeks with 9 follow-up visits over 26 weeks after the first injection.

The EUFLEXXA(R) group showed an advantage over saline in pain reduction, with a larger mean decrease from baseline in pain scores: -25.7 (28.9) mm versus -18.5(32.5) mm respectively, with a least squares means of -6.6 mm (P=0.002). At 26 weeks, 145 (58%) of EUFLEXXA(R) subjects reported a greater than or equal to 20-mm improvement in pain based on the VAS scoring, compared with 120 (46%) in the other group (P=0.006). The percentage of Osteoarthritis Research Society International (OARSI) responders for the EUFLEXXA(R) group was also significantly greater than that in the other group (67% versus 59% (P=0.047). A subject is considered a responder if there is a high improvement in pain or function, or improvement in at least two of the following three categories: pain greater than or equal to 20% and absolute change greater than or equal to 10 mm, function greater than or equal to 20% and absolute change greater than or equal to 10 mm, and/or patient global assessment greater than or equal to 20% and absolute change.

About EUFLEXXA(R)

EUFLEXXA(R) (1% sodium hyaluronate) is the first non-avian derived* hyaluronic acid (HA) approved in the U.S. for treatment of knee pain due to osteoarthritis (OA). EUFLEXXA(R) is indicated for patients who have failed to get adequate pain relief either from simple pain medications, such as acetaminophen, or from exercise and/or physical therapy. The process used to manufacture EUFLEXXA(R) results in highly-purified HA with properties similar to the HA in healthy human synovial fluid.(2-4) EUFLEXXA(R) received approval from the U.S. Food and Drug Administration (FDA) on December 3, 2004, and became available to the public on November 8, 2005.

EUFLEXXA(R) should not be used in people who have had any previous allergic reaction to hyaluronate preparations or who have knee joint infections or skin diseases in the area of the injection site. Common adverse events reported were arthralgia (joint pain) and back pain. Temporary knee pain and swelling may occur after injection. Strict aseptic technique must be followed to avoid joint infection.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of infertility, urology, and orthopaedic products in the U.S. market. They include: BRAVELLE(R) (urofollitropin for injection, purified), MENOPUR(R) and REPRONEX(R) (menotropins for injection, USP), Novarel(R) (chorionic gonadotropin for injection, USP), ENDOMETRIN(R) (progesterone) Vaginal Insert, 100 mg, PROSED(R) DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, DEGARELIX for injection and EUFLEXXA(R) (1% sodium hyaluronate).

References

(1) Data on File, Ferring Pharmaceuticals

(2) Altman RD, Rosen JE. Six-month safety and efficacy of non-avian intra-articular hyaluronan in knee osteoarthritis (OA).

(3) Schiavinato A, Finesso M, Cortivo R, & Abatangelo G (2002). Comparison of the effects of intra-articular injections of Hyaluronan and its chemically cross-linked derivative (Hylan G-F20) in normal rabbit knee joints. Clin Exp Rheumatol 20, 445-454.

(4) Goomer RS, Leslie K, Maris T, & Amiel D (2005). Native hyaluronan produces less hypersensitivity than cross-linked hyaluronan. Clin Orthop Relat Res 239-245.

Source: Ferring Pharmaceuticals Inc

View drug information on Degarelix; Desmopressin Acetate.

New School For Children With Autism Opens In Burr Ridge, IL

Soaring Eagle Academy, a school for children with Autism and related disorders, announced that it has opened in Burr Ridge, Illinois. It is the first school in the Midwest to offer an innovative teaching model called DIR® /Floortime, which has been used successfully in other parts of the country. The school offers fresh strategies and brings hope to families who are searching for new ways to educate their child with Autism.

“Our educational model has never been offered in a Midwest school before,” said Deanna Tyrpak, President of the Board of Soaring Eagle Academy. “The principles we follow are used extensively in private therapy clinics throughout the Chicagoland area, as well as in schools in other parts of the country. This is the first time a school following Illinois Learning Standards as well as a DIR®/Floortime curriculum has been available to Chicago area children and their families.”

The DIR® /Floortime philosophy is based on the belief that individuals with Autism have great potential for interacting, communicating and thinking. Long-term studies support the effectiveness of its innovative strategies. Each child is respected as an individual and a unique curriculum is developed for each student, based on their own natural interests, developmental level and therapeutic goals. Students are cared for physically, intellectually, socially and emotionally while engaged in meaningful learning.

The public is invited to attend Soaring Eagle’s Ribbon Cutting Ceremony and Open House on Saturday, December 4, 2010 from 10:00 am to 12:00 noon. Tours of the school will be given and attendees will have an opportunity to speak directly with school founders and staff. The school is located at 8320 S. Madison Street in Burr Ridge, Illinois.

Source:

Soaring Eagle Academy